Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumbling as much as 24% at one point in premarket trading on Friday morning.
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.
Novo Nordisk stock just tanked 25%: here's what happened
Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their weight by 22.7% in a late-stage trial – lower than 25% it had originally expected.
Novo Nordisk shares plummet after weight-loss drug's disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Novo Nordisk stock plunges on obesity shot trial results
Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in its clinical trial. Yahoo Finance senior health reporter Anjalee Khemlani expands upon this story and compares Novo Nordisk's stock performance with that of GLP-1 drug competitor Eli Lilly (LLY).
Novo Nordisk Stock Eyes Worst Day, Week on Record
Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's weight loss drug CagriSema missed expectations of a late-stage study.
Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial
Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible dosing protocol led to fewer patients reaching the highest dose, impacting the overall efficacy results.
PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded
Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo Nordisk (NVO) slid sharply after disappointing clinical data for its new obesity drug CagriSema.
Novo Nordisk Stock: A Rare Buying Opportunity
As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).
Novo Nordisk shares drop after weight loss drug trial disappoints
Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.
